<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Whole Body Checkup Report - Leukemia Patient</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            margin: 20px;
            line-height: 1.6;
        }
        h1, h2, h3 {
            color: #333;
        }
        .container {
            max-width: 800px;
            margin: auto;
            padding: 20px;
            border: 1px solid #ccc;
            border-radius: 8px;
            background-color: #f9f9f9;
        }
        table {
            width: 100%;
            border-collapse: collapse;
            margin-top: 20px;
        }
        th, td {
            padding: 10px;
            text-align: left;
            border-bottom: 1px solid #ddd;
        }
        th {
            background-color: #f2f2f2;
        }
    </style>
</head>
<body>

<div class="container">
    <h1>Whole Body Checkup Report</h1>
    
    <h2>Patient Information</h2>
    <p><strong>UID:</strong> 123456789</p>
    <p><strong>Date of Birth:</strong> January 15, 1996</p>
    <p><strong>Age:</strong> 28</p>
    <p><strong>Gender:</strong> Male</p>
    <p><strong>Date of Report:</strong> December 21, 2024</p>
    <p><strong>Date of Diagnosis:</strong> October 15, 2024</p>

    <h2>Diagnosis</h2>
    <p><strong>Type of Leukemia:</strong> Acute Lymphoblastic Leukemia (ALL)</p>
    <p><strong>Classification:</strong> B-lymphoblastic leukemia</p>

    <h2>Clinical Presentation</h2>
    <ul>
        <li>Fatigue and weakness</li>
        <li>Easy bruising and bleeding (petechiae)</li>
        <li>Frequent infections (e.g., fever, chills)</li>
        <li>Bone pain (especially in the long bones)</li>
        <li>Lymphadenopathy (swollen lymph nodes)</li>
    </ul>

    <h2>Laboratory Results</h2>
    <table>
        <thead>
            <tr>
                <th>Test</th>
                <th>Result</th>
                <th>Normal Range</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>White Blood Cell Count</td>
                <td>150,000 cells/µL</td>
                <td>< 10,000 cells/µL</td>
            </tr>
            <tr>
                <td>Hemoglobin</td>
                <td>8.5 g/dL</td>
                <td>13.5-17.5 g/dL</td>
            </tr>
            <tr>
                <td>Platelets</td>
                <td>30,000 cells/µL</td>
                <td>150,000-450,000 cells/µL</td>
            </tr>
            <tr>
                <td>Cytogenetics (BCR-ABL)</td>
                <td>Positive for Philadelphia chromosome</td>
                <td>N/A</td>
            </tr>
        </tbody>
    </table>

    <h2>Genetic Information</h2>
    <table>
        <thead>
            <tr>
                <th>Gene</th>
                <th>Description</th>
                <th>Cytogenetic Code/Alteration</th></tr></thead><tbody><tr><td>PAX5</td><td>Lymphoid transcription factor associated with B-cell development.</td><td>-</td></tr><tr><td>IKZF1</td><td>A transcription factor involved in lymphocyte development; mutations are linked to poor prognosis.</td><td>-</td></tr><tr><td>BCR-ABL1</td><td>A fusion gene resulting from the translocation between chromosomes 9 and 22; associated with Ph+ ALL.</td><td>(9;22)(q34;q11)</td></tr><tr><td>TEL-AML1 (ETV6-RUNX1)</td><td>A fusion gene resulting from translocation; common in pediatric ALL.</td><td>(12;21)(p13;q22)</td></tr></tbody></table>

    <h2>Staging and Prognosis</h2>
    <p><strong>Risk Classification:</strong> High risk due to the presence of the Philadelphia chromosome.</p>
    <p><strong>Prognosis:</strong> The five-year survival rate is approximately 25% for patients with Ph+ ALL without treatment.</p>

    <h2>Treatment Plan</h2>
    <ul>
        <li><strong>Induction Therapy:</strong></li>
        <ul>
            <li>Chemotherapy regimen including Vincristine, Dexamethasone, Daunorubicin, and Asparaginase.</li>
        </ul>

        <li><strong>Targeted Therapy:</strong></li>
        <ul>
            <li>TKI: Imatinib to target BCR-ABL fusion protein.</li>
        </ul>

        <li><strong>Supportive Care:</strong></li>
        <ul>
            <li>Blood transfusions as needed for anemia.</li>
            <li>Antibiotics for infection prophylaxis.</li>
            <li>Regular monitoring of blood counts and liver function tests.</li>
        </ul>

        <li><strong>Follow-Up Schedule:</strong></li>
        <ul>
            <li>Weekly CBC for the first month during induction therapy.</li>
            <li>Monthly follow-up appointments post-induction to monitor response to treatment.</li>
        </ul>

    </ul>

    <h2>Recommendations</h2>
    <ul>
        <li>Mainly a balanced diet rich in nutrients to support overall health.</li>
        <li>Engage in light physical activity as tolerated to improve strength and well-being.</li>
        <li>Avoid exposure to infections; practice good hygiene.</li>
        <li>Psychological support and counseling may be beneficial due to the emotional impact of diagnosis and treatment.</li>
    </ul>

    <h3>Doctor's Signature:</h3>
    <p><strong>Dr. Jane Doe, MD</strong></p>

</div>

</body>
</html>

